ConductScience.org, home
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment
API referenceFor AI assistants

Trial · NCT04908189

Outcomes38

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

1 to 20 of 38

Download this page as JSON
TypeOutcomeTime framePopulationUnitsMeasured as
PRIMARYNumber of Participants Meeting American College of Rheumatology (ACR) 20 at Week 16Week 16All randomized participants of deucravacitinib and placebo as pre-specified in protocolParticipantsCOUNT_OF_PARTICIPANTS
SECONDARYChange From Baseline in Disease Activity Score 28 C-reactive Protein (DAS28-CRP) at Week 16Baseline, Week 16All randomized participants of deucravacitinib and placebo as pre-specified in protocol with DAS28-CRP baseline and post-baseline measurementsscore on a scaleMEAN
SECONDARYChange From Baseline in Health Assessment Quiestionnaire - Disability Index (HAQ-DI) at Week 16Baseline, Week 16All randomized participants of deucravacitinib and placebo as pre-specified in protocol with HAQ-DI baseline and post-baseline measurementsscore on a scaleMEAN
SECONDARYNumber of Participants Meeting Psoriasis Area and Severity Index 75 (PASI 75) at Week 16Week 16All randomized participants of deucravacitinib and placebo with at least 3% body surface area (BSA) and at least static physician's global assessment (sPGA) 2 at baseline as pre-specified in protocolParticipantsCOUNT_OF_PARTICIPANTS
SECONDARYChange From Baseline in the 36-item Short Form (SF-36) Physical Component Summary (PCS) Score at Week 16Baseline, Week 16All randomized participants of deucravacitinib and placebo as pre-specified in protocol with SF-36 PCS baseline and post-baseline measurementsScore on a scaleMEAN
SECONDARYNumber of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Leeds Enthesitis Index (LEI) at Week 16Week 16All randomized participants of deucravacitinib and placebo as pre-specified in protocol with enthesitis at baseline by LEIParticipantsCOUNT_OF_PARTICIPANTS
SECONDARYNumber of Participants Meeting Achievement of Minimal Disease Activity (MDA) at Week 16Week 16All randomized participants of deucravacitinib and placebo as pre-specified in protocolParticipantsCOUNT_OF_PARTICIPANTS
SECONDARYChange From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Score at Week 16Baseline, Week 16All randomized participants of deucravacitinib and placebo as pre-specified in protocol with FACIT-Fatigue baseline and post-baseline measurementsScore on a scaleMEAN
SECONDARYNumber of Participants Meeting Dactylitis Resolution at Week 16Week 16All randomized participants of deucravacitinib and placebo as pre-specified in protocol with tender dactylitis count \>=1 at baselineParticipantsCOUNT_OF_PARTICIPANTS
SECONDARYNumber of Participants Meeting American College of Rheumatology (ACR) 50 at Week 16Week 16All randomized participants of deucravacitinib and placebo as pre-specified in protocolParticipantsCOUNT_OF_PARTICIPANTS
SECONDARYNumber of Participants Meeting American College of Rheumatology (ACR) 70 at Week 16Week 16All randomized participants of deucravacitinib and placebo as pre-specified in protocolParticipantsCOUNT_OF_PARTICIPANTS
SECONDARYChange From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI)Baseline, Weeks 2, 4, 8, 12, 16All randomized participants of deucravacitinib and placebo as pre-specified in protocol with HAQ-DI baseline and post-baseline measurementsscore on a scaleMEAN
SECONDARYNumber of Participants Who Achieve a Clinically Meaningful Improvement in HAQ-DI Score at Week 16Week 16All randomized participants of deucravacitinib and placebo as pre-specified in protocol with HAQ-DI baseline and post-baseline measurementsParticipantsCOUNT_OF_PARTICIPANTS
SECONDARYNumber of Participants Meeting Psoriasis Area and Severity Index 75 (PASI 75)Weeks 4, 8, 12, 16All randomized participants of deucravacitinib and placebo with at least 3% body surface area (BSA) and at least static physician's global assessment (sPGA) 2 at baseline as pre-specified in protocolParticipantsCOUNT_OF_PARTICIPANTS
SECONDARYNumber of Participants Meeting Psoriasis Area and Severity Index 90 (PASI 90)Weeks 4, 8, 12, 16All randomized participants of deucravacitinib and placebo with at least 3% body surface area (BSA) and at least static physician's global assessment (sPGA) 2 at baseline as pre-specified in protocolParticipantsCOUNT_OF_PARTICIPANTS
SECONDARYNumber of Participants Meeting Psoriasis Area and Severity Index 100 (PASI 100)Weeks 4, 8, 12, 16All randomized participants of deucravacitinib and placebo with at least 3% body surface area (BSA) and at least static physician's global assessment (sPGA) 2 at baseline as pre-specified in protocolParticipantsCOUNT_OF_PARTICIPANTS
SECONDARYChange From Baseline in the 36-item Short Form (SF-36) Physical Component Summary (PCS) ScoreBaseline, Weeks 4, 12, 16All randomized participants of deucravacitinib and placebo as pre-specified in protocol with SF-36 PCS baseline and post-baseline measurementsScore on a scaleMEAN
SECONDARYNumber of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Leeds Enthesitis Index (LEI)Weeks 4, 8, 12, 16All randomized participants of deucravacitinib and placebo as pre-specified in protocol with enthesitis at baseline by LEIParticipantsCOUNT_OF_PARTICIPANTS
SECONDARYNumber of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Spondyloarthritis Research Consortium of Canada (SPARCC)Weeks 4, 8, 12, 16All randomized participants of deucravacitinib and placebo as pre-specified in protocol with enthesitis at baseline by SPARCCParticipantsCOUNT_OF_PARTICIPANTS
SECONDARYNumber of Participants Meeting Achievement of Minimal Disease Activity (MDA)Weeks 4, 8, 12, 16All randomized participants of deucravacitinib and placebo as pre-specified in protocolParticipantsCOUNT_OF_PARTICIPANTS

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04908189/outcomes

API referenceFor AI assistants